Literature DB >> 21224353

HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes.

Jingjing Wu1, Zhaojian Liu, Changshun Shao, Yaoqin Gong, Eva Hernando, Peng Lee, Masashi Narita, William Muller, Jinsong Liu, Jian-Jun Wei.   

Abstract

The AT-hook transcription factor HMGA2 is an oncogene involved in the tumorigenesis of many malignant neoplasms. HMGA2 overexpression is common in both early and late-stage high-grade ovarian serous papillary carcinoma. To test whether HMGA2 participates in the initiation of ovarian cancer and promotion of aggressive tumor growth, we examined the oncogenic properties of HMGA2 in ovarian surface epithelial (OSE) cell lines. We found that introduction of HMGA2 overexpression was sufficient to induce OSE transformation in vitro. HMGA2-mediated OSE transformation resulted in tumor formation in the xenografts of nude mice. By silencing HMGA2 in HMGA2-overexpressing OSE and ovarian cancer cell lines, the aggressiveness of tumor cell growth behaviors was partially suppressed. Global gene profiling analyses revealed that HMGA2-mediated tumorigenesis was associated with expression changes of target genes and microRNAs that are involved in epithelial-to-mesenchymal transition (EMT). Lumican, a tumor suppressor that inhibits EMT, was found to be transcriptionally repressed by HMGA2 and was frequently lost in human high-grade serous papillary carcinoma. Our findings show that HMGA2 overexpression confers a powerful oncogenic signal in ovarian cancers through the modulation of EMT genes.
© 2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21224353      PMCID: PMC4434602          DOI: 10.1158/0008-5472.CAN-10-2550

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

1.  Ink4a/Arf regulation by let-7b and Hmga2: a genetic pathway governing stem cell aging.

Authors:  Alexandros Tzatsos; Nabeel Bardeesy
Journal:  Cell Stem Cell       Date:  2008-11-06       Impact factor: 24.633

2.  HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity.

Authors:  Monica Fedele; Rosa Visone; Ivana De Martino; Giancarlo Troncone; Dario Palmieri; Sabrina Battista; Andrea Ciarmiello; Pierlorenzo Pallante; Claudio Arra; Rosa Marina Melillo; Kristian Helin; Carlo Maria Croce; Alfredo Fusco
Journal:  Cancer Cell       Date:  2006-06       Impact factor: 31.743

3.  A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation.

Authors:  Masashi Narita; Masako Narita; Valery Krizhanovsky; Sabrina Nuñez; Agustin Chicas; Stephen A Hearn; Michael P Myers; Scott W Lowe
Journal:  Cell       Date:  2006-08-11       Impact factor: 41.582

4.  HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer.

Authors:  Gerhild Fabjani; Dan Tong; Andrea Wolf; Sebastian Roka; Sepp Leodolter; Paul Hoecker; Michael Bernhard Fischer; Raimund Jakesz; Robert Zeillinger
Journal:  Oncol Rep       Date:  2005-09       Impact factor: 3.906

5.  Lumican expression is positively correlated with the differentiation and negatively with the growth of human osteosarcoma cells.

Authors:  Dragana Nikitovic; Aikaterini Berdiaki; Alexandros Zafiropoulos; Pavlos Katonis; Aristidis Tsatsakis; Nikos K Karamanos; George N Tzanakakis
Journal:  FEBS J       Date:  2007-12-17       Impact factor: 5.542

6.  Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival.

Authors:  Frank Bartel; Juliane Jung; Anja Böhnke; Elise Gradhand; Katharina Zeng; Christoph Thomssen; Steffen Hauptmann
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

7.  HMGA2 participates in transformation in human lung cancer.

Authors:  Francescopaolo Di Cello; Joelle Hillion; Alexandra Hristov; Lisa J Wood; Mita Mukherjee; Andrew Schuldenfrei; Jeanne Kowalski; Raka Bhattacharya; Raheela Ashfaq; Linda M S Resar
Journal:  Mol Cancer Res       Date:  2008-05       Impact factor: 5.852

8.  miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma.

Authors:  Richard Flavin; Paul Smyth; Ciara Barrett; S Russell; Hannah Wen; Jianjun Wei; Alex Laios; Sharon O'Toole; M Ring; K Denning; J Li; S Aherne; D Sammarae; N A Aziz; A Alhadi; Sephen P Finn; M Loda; Sheppard B; Orla Sheils; John J O'Leary
Journal:  Int J Gynecol Cancer       Date:  2009-05       Impact factor: 3.437

9.  HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias.

Authors:  Gennaro Chiappetta; Angelo Ferraro; Emilia Vuttariello; Mario Monaco; Francesca Galdiero; Veronica De Simone; Daniela Califano; Pierlorenzo Pallante; Gerardo Botti; Luciano Pezzullo; Giovanna Maria Pierantoni; Massimo Santoro; Alfredo Fusco
Journal:  Eur J Cancer       Date:  2008-03-28       Impact factor: 9.162

10.  Role of miR-29b on the regulation of the extracellular matrix in human trabecular meshwork cells under chronic oxidative stress.

Authors:  Coralia Luna; Guorong Li; Jianmimg Qiu; David L Epstein; Pedro Gonzalez
Journal:  Mol Vis       Date:  2009-11-28       Impact factor: 2.367

View more
  74 in total

1.  Comparative analysis of AKT and the related biomarkers in uterine leiomyomas with MED12, HMGA2, and FH mutations.

Authors:  Jia Xie; Julianne Ubango; Yanli Ban; Debabrata Chakravarti; J Julie Kim; Jian-Jun Wei
Journal:  Genes Chromosomes Cancer       Date:  2018-08-20       Impact factor: 5.006

2.  BRCA1-mediated signaling pathways in ovarian carcinogenesis.

Authors:  Tejaswita M Karve; Xin Li; Tapas Saha
Journal:  Funct Integr Genomics       Date:  2011-09-02       Impact factor: 3.410

3.  Learning regulatory programs by threshold SVD regression.

Authors:  Xin Ma; Luo Xiao; Wing Hung Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-20       Impact factor: 11.205

4.  HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases.

Authors:  Thea Eline Hetland; Arild Holth; Janne Kærn; Vivi Ann Flørenes; Claes G Tropé; Ben Davidson
Journal:  Virchows Arch       Date:  2012-04-04       Impact factor: 4.064

5.  FGF18 as a prognostic and therapeutic biomarker in ovarian cancer.

Authors:  Wei Wei; Samuel C Mok; Esther Oliva; Sung-hoon Kim; Gayatry Mohapatra; Michael J Birrer
Journal:  J Clin Invest       Date:  2013-09-09       Impact factor: 14.808

6.  Genome-wide analysis of HMGA2 transcription factor binding sites by ChIP on chip in gastric carcinoma cells.

Authors:  Lang Zha; Ziwei Wang; Weixue Tang; Neng Zhang; Gang Liao; Zhen Huang
Journal:  Mol Cell Biochem       Date:  2012-01-14       Impact factor: 3.396

7.  The High Mobility Group A proteins contribute to thyroid cell transformation by regulating miR-603 and miR-10b expression.

Authors:  Paula Mussnich; Daniela D'Angelo; Vincenza Leone; Carlo Maria Croce; Alfredo Fusco
Journal:  Mol Oncol       Date:  2013-01-17       Impact factor: 6.603

8.  siRNA-Mediated Silencing of HMGA2 Induces Apoptosis and Cell Cycle Arrest in Human Colorectal Carcinoma.

Authors:  Sahar Esmailzadeh; Behzad Mansoori; Ali Mohammadi; Dariush Shanehbandi; Behzad Baradaran
Journal:  J Gastrointest Cancer       Date:  2017-06

9.  Prognostic value of centromere protein-A expression in patients with epithelial ovarian cancer.

Authors:  Jun-Jun Qiu; Jun-Jie Guo; Tian-Jiao Lv; Hong-Yan Jin; Jing-Xin Ding; Wei-Wei Feng; Ying Zhang; Ke-Qin Hua
Journal:  Tumour Biol       Date:  2013-05-28

10.  Expression of HMGA2 in bladder cancer and its association with epithelial-to-mesenchymal transition.

Authors:  X Ding; Y Wang; X Ma; H Guo; X Yan; Q Chi; J Li; Y Hou; C Wang
Journal:  Cell Prolif       Date:  2014-02-26       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.